CFM
WHWK

Catalyst Funds Management’s Whitehawk Therapeutics WHWK Stock Holding History

Catalyst Funds Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.2K Buy
+27,011
New +$84.6K 0.02% 493
2024
Q4 		– Sell
-4,100
Closed -$8.45K – 1331
2024
Q3 		$8.45K Hold
4,100
– – ﹤0.01% 1207
2024
Q2 		$5.99K Buy
+4,100
New +$7.6K ﹤0.01% 1030

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Catalyst Funds Management's WHWK Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Whitehawk Therapeutics (WHWK) in Q1 2026: 27,011 shares worth $93.2K. The stake represents 0.02% of the portfolio and ranks #493 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in WHWK as recently as Q3 2024.

Catalyst Funds Management first reported a position in WHWK in Q2 2024 and has held it in 3 quarters since. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Catalyst Funds Management held 27,011 shares of Whitehawk Therapeutics worth $93.2K as of Q1 2026.
  • Whitehawk Therapeutics was a new Catalyst Funds Management position in Q1 2026.
  • Whitehawk Therapeutics made up 0.02% of Catalyst Funds Management's portfolio in Q1 2026, its #493 holding.
  • Catalyst Funds Management first reported a position in Whitehawk Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.